TransCode Therapeutics, Inc. Common Stock
Symbol: RNAZ (NASDAQ)
11.23
▼ (-0.04%) -0.005
Company Description:
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
Key Stats
- Today's Open: $11.02
- Today's High: $11.555
- Today's Low: $11
- Today's Volume: 13.32K
- Yesterday Close: $11.23
- Yesterday High: $11.8
- Yesterday Low: $11.145528
- Yesterday Volume: 12.21K
- Last Min Volume: 1
- Last Min High: $11.225
- Last Min Low: $11.225
- Last Min VWAP: $11.225
Company Profile
- Name: TransCode Therapeutics, Inc. Common Stock
- Website: https://www.transcodetherapeutics.com
- Listed Date: 2021-07-09
- Location: BOSTON, MA
- Market Status: Active
- CIK Number: 0001829635
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $9.36M
- Round Lot: 100
- Outstanding Shares: 833.68K
- Asset Type: CS
RECENT FILINGS FOR RNAZ
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-02 | 8-K | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | 10-Q | View |
| 2025-08-14 | SCHEDULE 13G | View |
| 2025-07-15 | DEF 14A | View |
| 2025-06-13 | 8-K | View |
| 2025-05-14 | 10-Q | View |
| 2025-05-07 | 8-K | View |
| 2025-05-05 | 8-K | View |
| 2025-05-02 | 8-K | View |
| 2025-04-30 | 10-K/A | View |
| 2025-04-21 | DEFA14A | View |
| 2025-04-21 | 8-K | View |
| 2025-04-16 | DEFA14A | View |
| 2025-04-15 | 10-K | View |
| 2025-04-11 | DEF 14A | View |
| 2025-04-02 | PRE 14A | View |
| 2025-03-31 | NT 10-K | View |
| 2025-03-25 | 8-K | View |
| 2025-03-25 | 424B5 | View |
Latest News on RNAZ